Conversely, FcγRIIB expression on lymphoma cells is a risk factor for anti-CD20 rituximab therapy failure due to FcγRIIB internalizing the CD20:rituximab complex and thereby reducing exposure of the opsonized lymphoma cell to the immune effector systems (186). Here, FCGR2B is linked to lymphoma.